Regarding its glucose-lowering actions in T2DM, GLP-1 stimulates the islet β-cell GLP-1R to potentiate insulin secretion in a glucose-dependent manner, and thus the GLP-1R agonist drug class harbors low overall risk for hypoglycemia. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.